ESTRO meets Asia 2024 - Abstract Book

S99

Interdisciplinary – CNS

ESTRO meets Asia 2024

17. Saida Y, Watanabe S, Abe T, Shoji S, Nozaki K, Ichikawa K, et al. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases. Thoracic cancer. 2019; 10: 2106-16. 18. Zheng X, Mu S, Wang L, Tao H, Huang D, Huang Z, et al. Factors for incidence risk and prognosis of synchronous brain metastases in pulmonary large cell carcinoma patients: a population-based study. BMC pulmonary medicine. 2023; 23: 12. 19. Matsuo T, Shibata S, Yasunaga A, Iwanaga M, Mori K, Shimizu T, et al. Dose optimization and indication of Linac radiosurgery for brain metastases. International journal of radiation oncology, biology, physics. 1999; 45: 931-9.

20. Jaboin JJ, Ferraro DJ, DeWees TA, Rich KM, Chicoine MR, Dowling JL, et al. Survival following gamma knife radiosurgery for brain metastasis from breast cancer. Radiat Oncol. 2013; 8: 131.

21. Wang W, Song Z, Zhang Y. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis. Archives of medical science : AMS. 2018; 14: 1298-307.

22. Odrázka K, Vanásek J, Vaculíková M, Petera J, Zouhar M, Zoul Z, et al. Conformal radiotherapy for prostate cancer--longer duration of acute genitourinary toxicity in patients with prior history of invasive urological procedure. Acta oncologica (Stockholm, Sweden). 2001; 40: 810-5.

36

Digital Poster

efficacy of whole-brain radiotherapy plus simultaneous integrated boost for brain metastases

Qian Bi, Xin Lian, Fuquan Zhang

Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Purpose/Objective:

To investigate the outcomes of SIB-WBRT in patients with brain metastases and analyze the impact of some factors on prognosis.

Material/Methods:

This single-arm retrospective study analyzed patients with brain metastases treated with received SIB-WBRT (40 Gy/20 doses of whole brain tissue and tumor tissue pushed to 56-60 Gy/20 doses) at Peking Union Medical College Hospital from September 2015 to December 2021. The primary endpoint was intracranial progression free survival (iPFS). Secondary endpoints included overall survival (OS), intracranial new foci, and tumor control. The Kaplan-Meier method was then used to depict and estimate iPFS, OS, intracranial new incidence, and tumor control. Finally, the Cox model was used to analyze the association between some relevant factors and outcomes.

Results: